Referred to the House Committee on Energy and Commerce.
The bill directs HHS, via the FDA Commissioner, to conduct a study on expanding safe, effective reprocessing of single-use medical devices. The study must prioritize patient safety, assess third-party versus in-house reprocessing, operational feasibility, financial and environmental impacts, and liability issues.
Liberal emphasizes environmental and access gains; conservatives emphasize safety and regulatory limits.
Relative to its intended legislative type, this bill is a well-scoped and specific study directive that identifies responsible officials, required subject areas, consultations, definitions, and a one-year reporting requirement.
The bill directs HHS, via the FDA Commissioner, to conduct a study on expanding safe, effective reprocessing of single-use medical devices.
The study must prioritize patient safety, assess third-party versus in-house reprocessing, operational feasibility, financial and environmental impacts, and liability issues.
HHS must consult federal and non-federal stakeholders and report to Congress within one year with device listings and recommendations.
Study-only, narrow scope and stakeholder focus increase prospects; implementation depends on legislative calendar and any industry pushback.
Relative to its intended legislative type, this bill is a well-scoped and specific study directive that identifies responsible officials, required subject areas, consultations, definitions, and a one-year reporting requirement. It lacks explicit resourcing and detailed methodological requirements.
Liberal emphasizes environmental and access gains; conservatives emphasize safety and regulatory limits.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes environmental and access gains; conservatives emphasize safety and regulatory limits.
Generally favorable: sees environmental waste reduction and lower healthcare costs as positive public-interest outcomes.
Emphasizes strict patient-safety standards, equity in access, and transparent oversight.
Notes that projected cost and environmental benefits are plausible but speculative until the study provides data.
Supportive of a well-scoped, evidence-based study; values data before policy changes.
Wants clear metrics on safety, cost-benefit, and implementation feasibility.
Cautious about unfunded mandates or rushed rollouts; accepts study as a prudent first step.
Cautiously open to a study that may lower healthcare costs, but skeptical of expanded federal intervention.
Concerned about liability, infection risk, and burdensome regulations that could follow.
Views this bill as acceptable only if results avoid prescriptive federal mandates; many impacts remain speculative.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Study-only, narrow scope and stakeholder focus increase prospects; implementation depends on legislative calendar and any industry pushback.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes environmental and access gains; conservatives emphasize safety and regulatory limits.
Study-only, narrow scope and stakeholder focus increase prospects; implementation depends on legislative calendar and any industry pushback.
Relative to its intended legislative type, this bill is a well-scoped and specific study directive that identifies responsible officials, required subject areas, consultations, definitions, and a one-year reporting requ…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.